If Valeant stock is tempting, Gilead Sciences offers a cure
October 27, 2015 at 04:01 AM EDT
Before buying shares of Valeant Pharmaceuticals International, look at Gilead Sciences as an example of a drug maker doing things right, writes Tim Mullaney.
